V-10153 (Vernalis).
Vernalis is developing V-10153, a recombinant plasminogen activator stimulator, for the potential treatment of thrombotic disorders and cardiovascular disease. By March 2004, a phase II trial in acute myocardial infarction had been completed, and by July 2005, Vernalis intended to initiate a phase II trial in stroke later that same year.
Kamali
Farhad
F
Wolfson Unit of Clinical Pharmacology, University of Newcastle-upon-Tyne, NE1 7RU, UK. Farhad.Kamali@newcastle.ac.uk
D000818:Animals; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy; D010958:Plasminogen / Q000138:chemical synthesis / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D013329:Structure-Activity Relationship
C501338:BB-10153; D005343:Fibrinolytic Agents; D010958:Plasminogen